Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

Technology appraisal guidance
Reference number: TA864
Published: 01 February 2023

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 151 KB)

Published:

01 February 2023

Final draft guidance

Final draft guidance
Final appraisal document (PDF 197 KB)

Published:

14 December 2022
Committee papers (PDF 4.48 MB)

Published:

14 December 2022

Invitation to participate

Final scope (PDF 184 KB)

Published:

08 April 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 341 KB)

Published:

08 April 2022
Final stakeholder list (PDF 179 KB)

Published:

08 April 2022
Equality impact assessment (Scoping) (PDF 130 KB)

Published:

08 April 2022

Draft scope documents

Consultation document Draft scope (PDF 190 KB)

Published:

16 March 2022
Provisional Stakeholder List (post-referral) (PDF 173 KB)

Published:

16 March 2022